Google
MDXH Stock Analysis — MDXHEALTH SA ADR (Healthcare >> Diagnostics & Research)
MDXH FAQ
What is MDXH's ROE?
MDXHEALTH SA ADR reports a Return on Equity (ROE) of 437.67%.
What is MDXH's dividend yield?
MDXHEALTH SA ADR offers a dividend yield of 0.00%.
What is MDXH's Quality Score?
Our AI rates MDXH's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy MDXH?
Our AI Timing Score for MDXH is 28 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does MDXH belong to?
MDXHEALTH SA ADR is classified under the Healthcare >> Diagnostics & Research sector on the NASDAQ exchange
MDXH AI Analysis Summary
Our AI summary for MDXH: MDXHEALTH SA ADR (NASDAQ), Healthcare >> Diagnostics & Research sector. The stock currently trades at a P/E of 0.00, ROE of 437.67%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 28/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 0.42
Price
0.01
(2.53%)
Day Change
|
|
|---|
MDXH, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | N/A |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.42 |
| PBV / Sector |
-1.73 / -29.69
|
| Earning Per Share | -1.06 |
| PE / Sector |
N/A / 48.18
|
| PEG or PE/Growth / Sector |
N/A / 1.64
|
| Average 1M Daily Value |
0.13 M
GREAT
|
| Average 1W Daily Value |
0.06 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
37% |
| Ability to Make Profit |
|
56% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-01 08:00:09 |
| Symbol | MDXH |
| Name | MDXHEALTH SA ADR |
| Sector | Healthcare >> Diagnostics & Research |
| Market | NASDAQ |
| Listed Shares | 51.36 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 20.94 / 38,081.42 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: CAP Business Center, Herstal, Belgium, 4040
Phone: 866 259 5644
Website: https://mdxhealth.com
Employees: 364
Description: MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; ExoD, a non-invasive urine test to assess risk of having clinically prostate cancer; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. It offers genomic prostate score, which provides personalized genomic insights to physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. The company sells its products through urology sales force consisting of direct sales representatives, strategic account managers, and regional sales managers. The company has a collaboration the initiation of Genomic Prostate Score (GPS) testing. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Diagnostics & Research
Click a bubble to view stock details · Bubble size represents market capitalization share
